These analyses have highlighted important considerations for the use of INO, including its good activity irrespective of bone marrow blast percentage, extramedullary involvement, or CD22 expression, and its activity in Philadelphia chromosome (Ph)-positive ALL [13–15]. The gene discussed is CD22; the disease is acute lymphoblastic leukemia.